1. Home
  2. ABUS vs ALRS Comparison

ABUS vs ALRS Comparison

Compare ABUS & ALRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.40

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

ALRS

Alerus Financial Corporation

HOLD

Current Price

$32.58

Market Cap

751.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
ALRS
Founded
2005
1879
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
839.5M
751.6M
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
ABUS
ALRS
Price
$4.40
$32.58
Analyst Decision
Strong Buy
Hold
Analyst Count
1
6
Target Price
$5.00
$25.40
AVG Volume (30 Days)
2.7M
258.3K
Earning Date
05-14-2026
04-29-2026
Dividend Yield
N/A
3.26%
EPS Growth
55.26
N/A
EPS
0.87
0.89
Revenue
$14,083,000.00
N/A
Revenue This Year
N/A
$38.42
Revenue Next Year
$239.71
$4.68
P/E Ratio
$5.14
$36.15
Revenue Growth
128.21
N/A
52 Week Low
$3.25
$20.26
52 Week High
$5.38
$32.64

Technical Indicators

Market Signals
Indicator
ABUS
ALRS
Relative Strength Index (RSI) 43.60 68.41
Support Level $4.16 $30.13
Resistance Level $4.69 $32.64
Average True Range (ATR) 0.24 0.73
MACD -0.06 0.00
Stochastic Oscillator 11.95 91.39

Price Performance

Historical Comparison
ABUS
ALRS

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About ALRS Alerus Financial Corporation

Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and others. The company provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services and wealth management services, including retirement plans, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.

Share on Social Networks: